Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QAT370 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | QAT370 |
| 2 | PLACEBO_COMPARATOR | Placebo |
| 3 | ACTIVE_COMPARATOR | Tiotropium |
| Name | Type | Description |
|---|---|---|
| QAT370 | DRUG | - |
| Placebo | DRUG | - |
| Tiotropium | DRUG | - |
Inclusion Criteria: * Patients between 40 and 80 years of age with controlled COPD. * Women must be surgically sterilized or postmenopausal. Additional birth control and post-menopausal information will be available at time of enrollment. * Body mass index (BMI) must be within the range of 18 to 32...
QAT370 is an investigational small molecule being developed by Novartis AG for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is currently in Phase 1 clinical development, meaning it has not yet been approved and is still being studied for safety and tolerability in patients.
The molecular target of QAT370 has not been disclosed. It is a small molecule being studied for its safety and tolerability in patients with Chronic Obstructive Pulmonary Disease, but its specific mechanism of action is not publicly available.
QAT370 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 1 clinical trials for Chronic Obstructive Pulmonary Disease.
QAT370 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 1 trial has been completed, but the drug remains in early-stage clinical testing for Chronic Obstructive Pulmonary Disease.
QAT370 has one completed Phase 1 clinical trial registered as NCT00532350, titled "Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease." The trial enrolled 22 participants in Germany and was a randomized, double-blind, placebo-controlled study.
No, QAT370 is not the same as tiotropium. In the Phase 1 clinical trial NCT00532350, QAT370 was compared to tiotropium, which is an approved treatment for Chronic Obstructive Pulmonary Disease. QAT370 is a separate investigational drug being studied for the same condition.